SCTX

EX-99.1

2 sctx-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Scribe Therapeutics Reports Second Quarter 2026 Financial Results

and Recent Corporate Highlights

Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering without permanent genetic changes

Awarded more than $25 million from the California Institute for Regenerative Medicine (CIRM) to advance both STX-1200 for Lp(a) lowering and STX-1400 for triglyceride lowering toward clinical entry

Completed upsized initial public offering, including full exercise of the underwriters’ purchase option, and a concurrent private placement to Sanofi, generating approximately $155.5 million in aggregate gross proceeds

Cash, cash equivalents, and marketable securities of $43.0 million as of June 30, 2026, plus approximately $140.6 million of net proceeds raised from the July 2026 IPO and concurrent private placement, provides funding into the first half of 2029

ALAMEDA, Calif., September 2, 2026 – Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today reported financial results for the second quarter ended June 30, 2026, and provided recent corporate and pipeline updates.

“The second quarter and the weeks immediately following represented a transformational period for Scribe,” said Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe Therapeutics. “We advanced our lead silencing asset STX-1150 into the clinic, secured significant grant support from CIRM to develop our next two cardiometabolic assets, and successfully completed our initial public offering. These achievements position us to execute across a broadly differentiated portfolio of CRISPR genetic medicines designed to address the three major lipid drivers of atherosclerotic cardiovascular disease: LDL-C, Lp(a), and triglycerides. Our purpose-built technologies are uniquely poised to democratize access to the cardioprotective effects of beneficial human genetics. Guided by nature's blueprint for improved cardiovascular health, our aim is to shift the treatment paradigm of heart disease from chronic intervention of symptoms toward durable disease prevention and lifespan extension.”

Pipeline Highlights

STX-1150: In vivo epigenetic silencing therapy for LDL-C lowering

• Initiated first-in human Phase 1 clinical trial in Australia for Scribe's epigenetic silencing therapy STX-1150

o STX 1150 utilizes our Epigenetic Long-term X Repressor (ELXR) and is designed as a liver-targeted, in vivo CRISPR-based epigenetic silencing therapy that represses PCSK9, a genetically and clinically validated target for LDL-C lowering, without permanently altering the underlying DNA sequence.

o The Phase 1 study, initiated in mid-2026, will evaluate the safety, tolerability, and efficacy of STX-1150 in adults with elevated low-density lipoprotein cholesterol (LDL-C) and increased risk of atherosclerotic cardiovascular disease (ASCVD).

• Presented late-breaking data at the European Atherosclerosis Society (EAS) Congress supporting STX-1150 for persistent LDL-C lowering after a single dose.

o In non-human primates (NHPs), a single administration of an STX-1150 ELXR prototype demonstrated PCSK9 silencing of up to 90%, leading to LDL-C reductions of up to 68%.

o A therapeutically relevant dose of 0.75 mg/kg produced durable LDL-C reductions of greater than 50%, sustained for two years, with liver enzyme profiles comparable to saline controls.

o A toxicology study in NHPs showed no adverse clinical observations.

• Epigenetic silencing with STX-1150 is designed to address a major limitation of current LDL-C lowering approaches and is positioned to recapitulate the cardioprotective effects of human genetics.

o Current LDL-C therapies remain limited by adherence and durability: recent studies show 50 to 70% of patients discontinue LDL-C-lowering medicine within one year, increasing heart attack risk, while evidence indicates lifelong and earlier LDL-C lowering can deliver substantially greater ASCVD risk reduction than late or inadequate treatment.

o STX-1150 is designed to overcome this gap by using ELXR, Scribe’s highly engineered epigenetic silencing technology, to down-regulate PCSK9 transcription and deliver persistent, potent LDL-C reductions for years without permanently altering DNA.

o STX-1150 aims to mimic the protective cardiovascular profile seen in people with naturally occurring PCSK9 loss-of-function variants, who can have a 28% lower mean LDL-C, with up to 88% lower coronary heart disease risk. By doing so, STX-1150 should help shift LDL-C management from burdensome chronic treatment toward durable, long-term prev